Table 4.
Summary of literature on SRS for renal cell brain metastasis.
| Study | Year | Number of patients | Number of lesions | Median tumor volume (cm3) | Dose range (Gy) | Radiosurgery device | Median overall survival (months) | One-year local control (%) | One-year distant progression-free survival (%) |
|---|---|---|---|---|---|---|---|---|---|
| Present study | 2014 | 66 | 207 | 0.688 | 12–30 | Cyberknife | 13.9 | 84% (SRS only) 94% (Surgery + SRS) 88% (WBRT + SRS) |
35.2 |
|
| |||||||||
| Seastone et al. [31] | 2014 | 166 | 487 | 1.96 | 12–35 | Gamma knife | ND | 90a | ND |
|
| |||||||||
| Lwu et al. [32] | 2013 | 16 | 41 | 0.4f | 15–25 | Gamma knife | ND | 91 | ND |
|
| |||||||||
| Kim et al. [9, 14] | 2012 | 46 | 99 | 3.0b | 12–25 | Gamma knife | 10 | 84.7a | ND |
|
| |||||||||
| Kano et al. [29] | 2011 | 158 | 531 | 2.8 | 10–22 | Gamma knife | 8.2 | 86 | 45 |
|
| |||||||||
| Nieder et al. [43] | 2011 | 35 | ND | ND | ND | ND | 10.1 | ND | ND |
|
| |||||||||
| Lo et al. [33] | 2011 | 14 | 22 | 4b,f | 15–22f | Gamma knife | 6.5f | 95.5a | 40.2f |
|
| |||||||||
| Fokas et al. [24] | 2010 | 51 | ND | ND | 15–22 | LINAC | 12 | 81 | ND |
|
| |||||||||
| Marko et al. [34] | 2010 | 19 | 59 | 1.72b | 21.3b | Gamma knife | 12.58 | 95a | ND |
|
| |||||||||
| Hara et al. [44] | 2009 | 18 | 145f | 1.47f | 14–24f | Cyberknife | 14.2 | 87f | 38f |
|
| |||||||||
| Shuch et al. [45] | 2008 | 138 | ND | 1.7 | ND | ND | 10.7j | ND | ND |
|
| |||||||||
| Powell et al. [35] | 2008 | 23 | 303g | ND | 8–30g | Gamma knife | 5.1g | 93.6 | 37.3g |
|
| |||||||||
| Jensen et al. [21] | 2008 | 28 | 59 | 0.9 | 15–22 | LINAC | 7.03f | 60.9a | ND |
|
| |||||||||
| Samlowski et al. [36] | 2008 | 32 | 71 | 0.03–26.9d | 15–24 | LINAC | 6.7 | 86 | ND |
|
| |||||||||
| Shuto et al. [30] | 2006 | 69 | 314 | 1.5b | 8–30 | Gamma knife | 9.5 | 82.6a | ND |
|
| |||||||||
| Manon et al. [46] | 2005 | 14 | ND | ND | 15–24g | ND | 8.3g | 67.8g,h | 67.8g,h |
|
| |||||||||
| Chang et al. [16] | 2005 | 77 | 99 | 1.5 | 15–24 | LINAC | 9.1 | 64.3 | 60 |
|
| |||||||||
| Muacevic et al. [37] | 2004 | 85 | 376 | 1.2 | 15–35 | Gamma knife | 11.1 | 94a | ND |
|
| |||||||||
| Noel et al. [19] | 2004 | 28 | 65 | 1.28 | 10.9–22.3 | LINAC | 11 | 93 | 70 |
|
| |||||||||
| Sheehan et al. [7] | 2003 | 69 | 146 | 2.8 | 12.5–32 | Gamma knife | 6 | 96a | ND |
|
| |||||||||
| Petrovich et al. [47] | 2002 | 29 | 70 | ND | 20c | Gamma knife | 12 | ND | ND |
|
| |||||||||
| Hernandez et al. [17] | 2002 | 29 | 92 | 4.7 | 13–30 | Gamma knife | 7 | ND | ND |
|
| |||||||||
| Siebels et al. [38] | 2002 | 58 | 277 | 3.4 | 15–35 | Gamma knife | 9.9 | 95a | ND |
|
| |||||||||
| Wowra et al. [39] | 2002 | 75 | 350 | 1.6 | 15–35 | Gamma knife | 11 | 95i | ND |
|
| |||||||||
| Hoshi et al. [18] | 2002 | 42 | 110 | 1.5c,e | 20–30 | Gamma knife | 12.5 | 93a | ND |
|
| |||||||||
| Gerosa et al. [40] | 2002 | 74 | 102 | ND | 22b | Gamma knife | 14.6 | 86a | ND |
|
| |||||||||
| Brown et al. [15] | 2002 | 16 | ND | ND | 12–25 | Gamma knife | 17.8 | 85a | ND |
|
| |||||||||
| Amendola et al. [20] | 2000 | 22 | ND | 3.9b | 15–22 | Gamma knife | 8 | 98.5a | ND |
|
| |||||||||
| Payne et al. [41] | 2000 | 21 | 37 | 4.4 | 10.5–40 | Gamma knife | 8 | 100a | ND |
|
| |||||||||
| Goyal et al. [42] | 2000 | 29 | 66 | 1.135 | 7–24 | LINAC and Gamma knife | 6.7 | 91a | ND |
|
| |||||||||
| Schöggl et al. [8] | 1998 | 23 | 44 | ND | 8–30 | Gamma knife | 11 | 96a | ND |
|
| |||||||||
| Mori et al. [28] | 1998 | 35 | 52 | 2.4b | 13–20 | Gamma knife | 11 | 90a | ND |
ND: not defined, LINAC: linear accelerator.
aCrude.
bMean.
cMedian.
dRange.
emm tumor diameter.
fFor melanoma and RCC.
gFor melanoma, RCC, and sarcoma.
hAt 6 months.
iAt 1.5 years.
jFrom the time of diagnosis of the first brain metastasis.